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Abstract In this work, we illustrate the usefulness of
cyclodextrins, namely, methyl-b-cyclodextrin (MbCD),
an amorphous, methylated derivative of the natural
b-cyclodextrin (bCD), as a tool to form an inclusion
complex with omeprazole (OME), a poorly water sol-
uble drug. Solid binary systems between OME and
MbCD were prepared experimentally in a stoichiom-
etry 1:1 by different techniques (physical mixing,
kneading, spray-drying and freeze-drying). Afterward
these products were characterized by Fourier trans-
form-infrared spectroscopy (FTIR); X-ray diffractom-
etry (XRPD) and scanning electron microscopy
(SEM). The results obtained suggest that spray-drying
and freeze-drying methods yield a higher degree of
amorphous entities suggesting the formation of inclu-
sion complexes between OME and MbCD.
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Introduction
The ultimate mediator of acid secretion is the H+/K+-
ATPase. This pump is unique to the parietal cells and a
number of specific inhibitors of it have, therefore, been
developed. The available compounds belong to the
family of substituted benzimidazoles: omeprazole
(OME), lansoprazole, pantoprazole and rabeprazole
[1]. In the acid space of the secreting parietal cells
these compounds are converted to thiophilic sulfon-
amide or sulfenic acid which reacts mainly with the
Cys-813 residue in the catalytic subunit of the H+/K+-
ATPase, which is critical for enzyme inactivation [2].
OME, the primary member of the proton pump
inhibitors, has been extensively used to control acid
disorders. However, the main pharmaceutical draw-
backs are mainly related to the physicochemical
instability to heat, light and acidic media, even with
coated formulations. Moreover the low aqueous solu-
bility of OME (~0.4% at 25 C) is responsible for small
dissolution rates and hence low bioavailability [3]. In
recent years, to overcome the drugs stability and
solubility limitations, several approaches have been
investigated. Cyclodextrins (CDs) have been exten-
sively used as complexing agents to improve solubility
and stability of a variety of poorly soluble and labile
drugs. Natural CDs have limited water solubility that
negatively influences water solubility of the formed
complex. To overcome this problem alkyl moiety, such
as hydroxyalkyl or methyl, on free hydroxyl groups of
bCD were introduced. The complexing ability of CD
derivatives was significantly modified in respect to the
parents [4].
Therefore the purpose of this work was to investi-
gate the ability of MbCD to include OME and to
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perform the physicochemical characterization of
the inclusion complex formed in solid state by
Fourier transform-infrared spectroscopy (FTIR), X-ray




Methyl-beta-cyclodextrin, MbCD (Lot 768240; MW =
1190 and an average degree of substitution, DS = 0.5)
was a gift from Roquette (Lestrem, France) and OME
(Lot 18104; MW = 345.42) was kindly donated by
Belmac Laboratory, S.A. (Barcelona, Spain). All other
chemicals and solvents were of analytical grade.
Preparation of solid binary systems
The preparation of OME:MbCD solid systems was
performed in 1:1 molar ratio by kneading, spray-drying
and freeze-drying. Physical mixtures were prepared as
reference to perform comparative evaluations with
solid inclusion complexes.
Physical binary mixture (PM)
PM was prepared by homogeneous blending in a
mortar of previously sieved (63–160 lm sieve granu-
lometric fraction) and weighted OME and MbCD.
Kneaded binary product (KN)
MbCD was wetted in a ceramic mortar with a basic
aqueous solution with pH of 10 ± 0.1 until a paste was
obtained (about 30% of the total weight). The required
amount of OME was then slowly added and the slurry
was kneaded for about 45 min. During this process an
appropriate volume of the basic aqueous solution was
added in order to maintain a suitable consistency and
to avoid OME degradation. The final product was then
allowed to equilibrate at room temperature for 48 h
protected from light.
Spray-dried binary product (SD)
Equimolar amounts of OME and MbCD were dis-
solved in ethanol and basic aqueous solution
(pH = 10 ± 0.1), respectively. Both solutions were
mixed and stirred for 24/48 h, being the pH of the
solutions adjusted during the process to avoid the pos-
sible OME degradation. Solutions were subsequently
spray dried in a LabPlant SD-05, under the following
conditions: inlet temperature 102 C, outlet tempera-
ture 60–65 C, flow rate of the solution 400 ml/h, air-
flow rate 40–50 m3/h and atomizing air pressure 1.0–1.1
bar. [5].
Lyophilized binary product (LPh)
An appropriate amount of MbCD was dissolved to a
basic aqueous solutions (pH = 10 ± 0.1). After that,
OME was added to this solution under stirring,
according to the stoichiometry 1:1. The solution stir-
ring was maintained for 24/48 h. Furthermore, the
resultant clear solution was frozen by immersion in an
ethanol-bath at –50 C (Shell Freezer, Labconco,
Freezone model 79490) and then the frozen solution
was lyophilized in a freeze-dryer (Lyph-lock 6 appa-
ratus, Labconco) for 72 h.
The obtained powders were sieved (63–160 lm) and
their drug content was determined by UV assay at
305.5 nm.
X-ray powder diffraction (XRPD)
X-ray powder diffraction patterns of OME, MbCD and
binary systems (PM and inclusion complexes) were
obtained at room temperature with a Philips X’Pert,
model PW 3040/00 diffractometer system equipped
with Co as anode material and a graphite monochro-
mator using a voltage of 40 kV and a current of 35 mA.
The difractograms were recorded in the 2h angle range
between 5 and 50 and the process parameters were set
at: scan step size of 0.025 (2h); scan step time of 1.25 s;
and acquisition time of 1 h.
Scanning electron microscopy (SEM)
The surface morphology of the raw materials and bin-
ary systems (PM and inclusion complexes) were
examined by means of a scanning electron microscope
(Jeol, JSM 5310, Tokyo, Japan). The samples were fixed
on a brass stub using double-sided tape and then made
electrically conductive by coating in vacuum with thin
layer of copper. The photographs were taken with a
Pentax (model MZ-10) camera at an excitation voltage
of 10 KV and magnifications factors of 500 and 3500.
Fourier transform infrared spectroscopy (FTIR)
OME, MbCD, PM and inclusion complexes spectra were
recorded using a Jasco FT/IR-420 spectrometer associ-
ated with an ATR horizontal reflexion (MiracleTM,
PIKE Technologies). Spectra acquisitions were per-
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formed directly in powder samples with the application
of 16 scans at a resolution of 4 cm–1 over the range 4000–
400 cm–1.
Results
X-ray powder diffraction (XRPD)
The X-ray powder diffractograms of the pure compo-
nents (OME and MbCD), PM and inclusion com-
plexes, are shown in Fig. 1 and peak intensities are
presented in Table 1. The XRPD patterns of OME
revealed several diffraction peaks which are indicative
of its crystalline character, while a hollow pattern was
recorded for MbCD which comprove its amorphous
state. Comparing the diffraction patterns of pure
components with PM it was possible to observe that
diffractograms of PM resulted of the combination of
the components analyzed separately, with a marked
decrease in the intensity of the diffraction peaks, which
can be attributed to the amorphous character of this
CD and the reduction in particle size during the
preparation of the PM. The KN system presented a
diffraction pattern quite similar to that of PM. How-
ever, a lower intensity of it diffraction peaks and
overlapping between some OME and MbCD peaks
was also observed. This fact can be explained by the
presence of reciprocal interactions in the solid state
between host and guest. OME:MbCD SD and LPh
systems exhibited a complete amorphous character,
showing a typical flat behaviour that confirms the
strong ability of the amorphous carrier MbCD to
induce drug amorphization [6]. On the other hand, the
loss of the crystallinity state can be a consequence of
the lyophilization process and because of that X-ray
data could not discriminate whether the LPh product
obtained was a true inclusion complex or a homoge-
neous dispersed mixture of the amorphous components
[7]. However, in the case of OME:MbCD SD system
we could observe a diffraction pattern completely
diffuse, which revealed its amorphousness. This
behaviour could be attributed to an interaction
between OME and MbCD showing the presence of a
new solid phase where a possible formation of an
inclusion compound was contemplated [7]. Finally, it
was possible to observe that peaks intensities decrease
in the following order: PM > KN > SD > LPh systems
corroborating with the results previously report.
Scanning electron microscopy (SEM)
SEM photomicrographs of OME, MbCD and
OME:MbCD systems (PM and inclusion complexes)
are reported in Fig. 2. OME is characterized by regular
shaped crystals while MbCD is composed of amor-
phous spherical particles [8]. OME:MbCD PM showed
the presence of OME small crystals adhered on the
surface of CD particles. This fact demonstrated the
inexistence of apparent interactions between both
species in the solid state. In KN product, it was possible
to distinguish OME crystals agglomerated on the sur-
face of CD particles that had lost their original shapes
and a drastic change in the aspect of MbCD particles
were observed. SD sample showed the typical mor-
phology of preparations generally obtained by this
method, very small size spherical particles with high
tendency to aggregation [3], which were different
from those of raw materials. Finally, LPh product
appeared to have a less crystalline structure with a soft,
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Fig. 1 X-ray diffractograms of OME:MbCD inclusion com-
plexes. Omeprazole (OME), methyl-beta-cyclodextrin (MbCD),
physical mixture (PM), kneaded (KN), spray dried (SD) and
lyophilized (LPh) systems
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components were still not distinguishable [9]. We can
conclude that the changes of KN product when com-
pared with PM was due to the effect of the preparation
method in MbCD particles and not due to an inter-
action between both components [10]. On the other
hand, the drastic change of the particle shape and
aspect in SD and LPh products, which corroborates the
formation of a new solid phase, could be the simple
consequence of a crystalline habitus change in those
systems or it may support the evidence of the existence
of a single phase [5]. Although this technique is not
conclusive for assessing the existence of a true inclu-
sion compound in the solid state, it can be useful to
prove the homogeneity of the solid phases [3].
Fourier-transform infrared spectroscopy (FTIR)
The infrared spectra of different samples (OME,
MbCD, OME:MbCD PM and inclusion complexes) are
presented in Fig. 3. In FTIR spectra, C = C–N and
S–C = N stretching link vibrations (1626.7 cm–1) and
Ar–C–O–CH3 vibration (1203.4 cm
–1) accompanied by
the resonance band at 1075 cm–1 were used to assess the
interaction between MbCD and guest molecule (OME)
in the solid state [3]. We can observe that the intensity
of both bands is decreased when comparing spectra
recorded on the OME:MbCD complexes (KN, SD and
LPh) with those of the PM product. The intensity and
amplitude of the shifts verified on these bands were in
the following range: PM > KN > SD  LPh. In SD and
LPh systems, it can be observed that these bands almost
disappear, probably owing to a restriction of the
vibration related to the complexation process. The band
Table 1 Peak intensities of OME in the XRPD patterns of
OME-MbCD binary systems
2h OME OME:MbCD
MF MLX SD LPh
12,813 1785 691 669 470 393
14,288 3429 842 790 500 417
22,912 1608 604 581 556 469
27,713 2573 553 538 339 266
29,838 1449 408 398 305 269
Omeprazole (OME), methyl-beta-cyclodextrin (MbCD), physi-
cal mixture (PM), kneaded (KN), spray dried (SD) and lyophi-
lized (LPh) systems






kneaded (D), lyophilized (E)
and spray dried (F) systems
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positioned at 1203.4 cm–1 is related to bending vibra-
tions of the methoxyl groups of OME and its behaviour
may be understood by the occurrence of a restriction
due to the inclusion within the cavity of MbCD. These
results were also corroborated by 1H-NMR experi-
ments under publication.
Conclusions
SEM, FTIR spectroscopy and XRPD diffractometry
have been used to study the inclusion complexes
formed between OME and MbCD in solid phase.
Remarkable changes were detected in all character-
ization methods, indicating the promising formation of
new solid phases, some of them in amorphous state,
allowing to the conclusion of strong evidences of bin-
ary inclusion complex formation between OME and
MbCD, particularly for SD and LPh systems.
Taking in account these results, we can conclude
that the interaction of OME with MbCD, through
the formation of an inclusion complex, can lead
to important modifications on the physicochemical
properties (solubility, stability and consequently
bioavailability) of the guest molecule (OME). Those
modifications may have a significant impact on the
biological effects of the drug. Therefore, studies are
being performed to evaluate the potential biopharma-
ceutical effects of OME:MbCD product on a new drug
delivery system.
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Fig. 3 FTIR spectra (in absorbance) of OME:MbCD inclusion
complex. Omeprazole (OME), methyl-beta-cyclodextrin
(MbCD), physical mixture (PM), kneaded (KN), spray dried
(SD) and lyophilized (LPh) systems
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